Method for Treating Oncological, Virulent and Somatic Diseases, Method for Controlling Treatment Efficiency, Pharmaceutical Agents and Composition for Carrying Out Said Treatment

Abstract

The invention relates to medicine and veterinary science and discloses a novel method for treating oncological, virulent and somatic diseases whose main target for therapeutic action is embodied in the form of DNA which freely circulates in blood plasma (and other liquid media) and originates from tumoral and mutant cells or cells infected by bacteria, fungi or protozoan and from different microorganisms which reside in the organism thereof. Said invention also relates to novel pharmaceutical compositions and to the use thereof for treating oncological diseases and infectious states provoked by bacteria, fungi and protozoa and non-infectious somatic diseases and states produced by accumulation of somatic mutations in cells of organism. Medicinal and immunological compositions, sorption and physico-chemical engineering and the method for using them in order to treat malignant tumors and other diseases are also disclosed.

1 . Treatment method of oncological and/or infectious and/or somatic diseases by acting on biological targets inside organisms, differs in that the biological target is extracellular DNA including extracellular DNA circulating in blood plasma.  
     
     
         2 . Treatment method of oncological and/or infectious and/or somatic diseases according  claim 1  differs in that the extracellular DNA is inactivated by destruction, binding or modification.  
     
     
         3 . Treatment method of oncological and/or infectious and/or somatic diseases according  claim 1  and  2 , differs in that the extracellular DNA is inactivated by destruction, binding or modification by injecting to patient of pharmaceutical agent which is capable to destroy, bind or modify free circulating DNA.  
     
     
         4 . Treatment method of oncological and/or infectious and/or somatic diseases according claim  1 - 3 , differs in that the extracellular DNA is inactivated by destruction, binding or modification by pharmaceutical agent's injection in amount sufficient for destruction and in therapeutic regime providing destruction, binding or modification in sufficient for therapeutic effect achievement period of time.  
     
     
         5 . Treatment method of oncological and/or infectious and/or somatic diseases according claim  1 - 4  differs in that the genetically modified cells or genotherapeutic constructions are injected to patient when said remedies induce synthesis in host's organism of biopolymers, capable to inactivate free circulating blood plasma DNA by its binding, destruction or modification.  
     
     
         6 . Treatment method of oncological and/or infectious and/or somatic diseases according  claim 1  or  2 , differs in that the circulating extracellular DNA is inactivated by destruction, binding or modification using extracorporeal blood processing.  
     
     
         7 . Treatment method of oncological and/or infectious and/or somatic diseases according  claim 1 ,  2  or  6 , differs in that the extracorporal purification of patient's blood from free circulating DNA is achieved by immune or affine absorption.  
     
     
         8 . Treatment method of oncological and/or infectious and/or somatic diseases according  claim 1 ,  2  or  6 , differs in that the extracorporal purification of patient's blood from free circulating DNA is achieved by methods of gravitational blood surgery.  
     
     
         9 . Treatment method of oncological and/or infectious and/or somatic diseases according  claim 1 ,  2  or  6 , differs in that the extracorporal purification of patient's blood from free circulating DNA is achieved by biological, chemical or photochemical inactivation.  
     
     
         10 . Treatment method of oncological and/or infectious and/or somatic diseases according  claim 1  or  2 , differs in that the patient is immunized by vaccine, which vaccine contain blood plasma circulating DNA (including said DNA with naturally complexed proteins) as the antigen.  
     
     
         11 . Treatment method of oncological and/or infectious and/or somatic diseases according claims  1 - 10 , differs in that the treatment is combined with surgical, chemiotherapeutic, hormonal, radiation and immunotherapeutic methods.  
     
     
         12 . Pharmaceutical agent for oncological and/or infectious and/or somatic disease treatment, representing compound possessing desoxyribonuclease activity and/or being able to inactivate extracellular DNA including DNA circulating in patients blood plasma.  
     
     
         13 . Pharmaceutical agent according  claim 12  differs in that compound possessing desoxyribonuclease activity is desoxyribonuclease enzyme.  
     
     
         14 . Pharmaceutical agent according  claim 13  differs in that desoxyribonuclease is modified for better pharmacodynamic and pharmacokinetic performance and comprises desoxyribonuclease analogue with increased activity, desoxyribonuclease analogue not sensitive to endogenous inhibitors of desoxyribonuclease, polysialated desoxyribonuclease, pegylated desoxyribonuclease, desoxyribonuclease that is bound or mixed with synthetic and natural microspheres, liposomes, dextran, and other corpuscular natural and synthetic polymer carriers.  
     
     
         15 . Pharmaceutical agent according claims  12 - 14  which additionally contains ribonuclease and/or lipase and/or proteinase.  
     
     
         16 . Pharmaceutical agent according  claim 12 , differs in that the compound possessing desoxyribonuclease activity is antibody possessing nuclease activity, in particular polyclonal DNA-abzymes, monoclonal DNA-abzymes or their derivatives.  
     
     
         17 . Pharmaceutical agent according  claim 12 , differs in that the compound able to bind DNA is antibody able to bind DNA and its complexes and derivatives of said antibody.  
     
     
         18 . Pharmaceutical composition for oncological and infectious diseases treatment, containing pharmaceutical agent according claims  12 - 16  in therapeutically effective amount and pharmaceutically acceptable carrier or excipient.  
     
     
         19 . Method to increase the life time which is achieved by inactivation of extracellular DNA circulating in blood plasma by said DNA destruction, binding or modification according claims  2 - 17 .  
     
     
         20 . Method of prophylaxis of pathologies connected with appearance and development of somatic mosaicism by the way of destruction, binding or modification of DNA according to claims  2 - 17 .  
     
     
         21 . Method to control the treatment efficacy of oncological and/or infectious and somatic diseases, to estimate the infection development, to control the efficacy of treatment directed to prolongation of life time, by the way of measurement of patient biochemical factors, differs in that monitoring for control of such treatment sizes of molecules, fractions' correlation, bindings with proteins, lipids and sugars, nucleotide consequences of free circulating blood plasma DNA are used.  
     
     
         22 . Usage of blood plasma DNA and extracellular microbial DNA for evaluation of DNA involved in process of diseases' appearance and development, which usage includes its cloning, sequencing, identification of genes, unique and repeated sequences with their future studying.